HZNP News and Press, Horizon Therapeutics Public Limited Company From 02/23/22

-- Teprotumumab is marketed under the brand name TEPEZZA ® in the United States -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial (OPTIC-J) in Japan evaluating teprotumumab for the...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will present at the following conference in March: Cowen and Company 42 nd Annual Health Care Conference (Virtual) Date: Tuesday, March 8, 2022 Presentation time: 11:10 a.m. ET The prese...

The healthcare industry is growing rapidly on increasing demand and continuing advancements in therapies. Furthermore, this year is expected to be a transformative one for the healthcare sector, with a more robust transition to digital health. Given the industry's growth potential, Wall Stree...

Horizon Therapeutics (NASDAQ:HZNP) said a new analysis showed that Uplizna reduced the severity of attacks and levels of key disease-related biomarkers in people with Neuromyelitis Optica Spectrum Disorder (NMOSD). Uplizna is approved in the U.S. to treat NMOSD in adults who ar...

Horizon Therapeutics plc (Nasdaq: HZNP) today named Sean Clayton as executive vice president and general counsel effective Feb. 28. Sean will report directly to Tim Walbert, chairman, president and chief executive officer and will join the Company’s executive committee. ...

-- New data links UPLIZNA treatment to fewer severe attacks and reduced levels of key disease-related biomarkers versus placebo -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced results from a new analysis showing treatment with UPLIZNA effectively reduced the sever...

An analysis of post-marketing studies conducted by Horizon Therapeutics (HZNP +1.9%) on Tepezza (teprotumumab) found that the rate of hearing-related adverse events was similar to that seen in phase 3 trials. Tepezza, approved in 2020, is the only FDA-approved therapy for thyroid eye disease....

-- TEPEZZA analysis reinforcing sustained efficacy also presented at NANOS 2022 -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced results from a new post-marketing safety analysis of hearing events associated with TEPEZZA for the treatment of Thyroid Eye Disease (TE...

-- The original song inspired by a creative story written by Leanor, a 7-year-old who lives with a rare pediatric cancer -- -- The Doug the Pug and #RAREis Playlist music video will premiere Feb. 17 on the Doug the Pug and the Doug the Pug Foundation Instagram pages -- ...

HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive. For further details see: Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend